Amgen and MBC Biolabs announce winners of the Amgen Golden Ticket

AmgenAmgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) announced that Delve Therapeutics and Mitokinin have won the Amgen Golden Ticket at MBC BioLabs. Each company receives one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen's scientific and business leaders to help advance its scientific programs. Amgen first sponsored MBC BioLabs in 2015 to assist high-potential and innovative early-stage life science and biotech companies in their efforts to accelerate the development of new therapies to improve human health.

The 2018 Amgen Golden Ticket winners were chosen by a team of scientific leaders who evaluated the strength and novelty of their scientific rationale, subject matter expertise and business plan viability.

"Given Amgen's commitment to bringing first-in-class therapies for cancer and neuroscience-related conditions to patients, we are pleased to support Delve Therapeutics and Mitokinin in further advancing their novel science," said Flavius Martin, Ph.D., vice president of Research at Amgen. "Funding such early-stage innovation is critical to the future of healthcare, and both companies are well on their way to tackling complex research problems. Congratulations to both companies and to the promising scientific entrepreneurs that represent them."

Delve Therapeutics is an early-stage company researching new oncolytic viruses to treat metastatic cancers. Their team is investigating possible ways to use synthetic biology to make viruses tumor-selective without reducing their cancer cell-killing potential.

"The lab space provided by Amgen's Golden Ticket will accelerate our research by allowing us to conduct more experiments in one place," said Scott Becker, co-founder and chief business officer at Delve Therapeutics. "We also look forward to learning from Amgen’s scientists, who are at the forefront of clinical research in our field."

Mitokinin is a biotechnology company developing first-in-class small molecules targeting PINK1, a master regulator of mitochondrial quality control. Mitokinin believes that by selectively increasing PINK1's activity, its drugs can improve mitochondrial health and address several of the cellular dysfunctions commonly seen in Parkinson’s disease. With the Amgen Golden Ticket, Mitokinin plans to extend its PINK1 program to include Alzheimer’s disease, since mitochondrial problems are observed in that disease as well.

"We are very grateful to have been selected for Amgen's Golden Ticket," said Daniel de Roulet, chief executive officer at Mitokinin. "For nearly 40 years, Amgen has been at the forefront of biotechnology, leading the way in fields like genetic engineering and immuno-oncology. For a company as forward-thinking as Amgen to put its support behind us is a tremendous validation of our science and therapeutic approach. Thanks to Amgen's Golden Ticket, we are excited to expand the scope of our studies and work closely with the Amgen team to press forward with our mission to deliver disease-modifying therapies for neurodegenerative disease."

"One of the critical issues for startups is relentlessly focusing on what matters most. With a state-of-the-art infrastructure already in place, MBC BioLabs' ready-to-use facilities enable new companies to do an experiment in their first week rather than the first year because they don’t have to waste time with things like equipment set-up or permitting," said Doug Crawford, general manager at MBC BioLabs. "Our partnership with Amgen also allows our entrepreneurial scientists to gain access to expert scientific guidance."

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

About MBC BioLabs

MBC BioLabs provides space as small as a single bench in fully-equipped labs. Scientists can conduct experiments on their first day, cutting months and millions of dollars off the time and cost necessary to gather data. MBC BioLabs' facilities in San Francisco and San Carlos are home to 60 energetic young companies. Since opening its doors four years ago, MBC BioLabs tenant companies have raised over $1.8 billion dollars.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Japan becomes the first country to approve Roche's…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of a...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

FDA approves Amgen and Allergan's KANJINTITM (tras…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved ind...

Vitamin D may not help your heart

While previous research has suggested a link between low levels of vitamin D in the blood and an increased risk of cardiovascular disease, a new Michigan State University...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

Researchers identify enzyme that suppresses immune…

Immunotherapies have transformed cancer care, but their successes have been limited for reasons that are both complex and perplexing. In breast cancer especially, only a ...